What is TelyRx?
TelyRx operates as a high-growth digital health platform, effectively bridging the gap between licensed medical providers and patients requiring convenient, discreet access to medication. By leveraging a robust network of pharmacies and telehealth professionals, the company addresses critical gaps in healthcare accessibility. Its service model, which supports over 200,000 patients, focuses on streamlining the procurement of medications for chronic conditions, mental health, and lifestyle-related needs. By removing the friction of traditional in-person clinical visits, TelyRx has established itself as a significant player in the direct-to-consumer pharmaceutical space, prioritizing patient-centric care and operational efficiency.
How much funding has TelyRx raised?
TelyRx has raised a total of $12.6M across 1 funding round:
Private Equity
$12.6M
Private Equity (2026): $12.6M, investors not publicly disclosed
Key Investors in TelyRx
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for TelyRx?
With this major enterprise-level funding, TelyRx is poised to transition into a phase of aggressive market expansion and technological integration. The strategic allocation of this capital will likely focus on enhancing the company's proprietary digital infrastructure, expanding its network of licensed providers, and optimizing supply chain logistics to ensure faster delivery times. As the telehealth sector continues to mature, TelyRx is expected to leverage its current momentum to explore new therapeutic categories and potentially integrate advanced diagnostic tools into its existing platform. This growth trajectory suggests a long-term commitment to redefining the patient experience through seamless, technology-enabled healthcare solutions.
See full TelyRx company page
